Air Freight vs. Ocean Freight for Class II Medical Device Shipping

Ocean shipping runs cheaper, the container books months in advance, and the unit cost math comes out cleanly in favor of the slower option. For most manufactured goods, that math holds. But for Class II medical devices, it frequently doesn’t. These 510(k)-cleared products have sterility requirements, shelf-life constraints, FDA documentation obligations, and customs screening exposure that affect the true cost of medical device shipping.

Why the Standard Freight Comparison Doesn’t Work for Class II Devices

The conventional air freight vs. ocean freight conversation is built around a commodity goods framework. It’s about weight, volume, transit time, and rate. That framework works when cargo has no regulatory documentation requirements, no sterility validation window, no FDA screening exposure, and no shelf-life clock running from the moment it leaves the production floor.

Class II medical devices have all of those variables, and every one of them adds a cost dimension that the standard comparison ignores. The result is a model that understates true landed cost. Class II devices occupy a specific risk tier that general freight logistics isn’t designed around. They’re frequently sterile, high-value relative to weight, and dependent on documentation that has to match FDA records exactly.

Choosing the right medical device time to market strategy means accounting for what happens after the device leaves the production floor, including what shipping lane it travels through.

What Ocean Freight Actually Costs for a Class II Device

Ocean freight’s true cost for medical device freight is the carrier invoice plus the mode-specific expenses that accumulate across transit time, compliance exposure, and inventory risk. None of those appear on the rate quote, but all of them flow through to landed cost.

Transit Time and Inventory Carrying Costs

A standard transpacific voyage runs 25 to 35 days before drayage and inland delivery are added. For a high-value Class II device shipment, every day in transit represents carrying cost on tied-up capital. That number is invisible in the standard freight comparison because it doesn’t appear on a logistics invoice. Multiplied across multiple shipments and SKUs annually, the carrying cost gap between ocean and air becomes a meaningful line item.

Sterility Window and Packaging Integrity Risk

Class II devices that ship in a validated sterile state carry a defined sterility assurance period. When packaging integrity is compromised during transit, the result is a potential compliance event requiring investigation, documentation, and possibly re-sterilization or product destruction. The biomedical supply chain risk associated with sterility failures during long voyages is one of the most consistently underestimated cost categories in medical device shipping.

Documentation Exposure and FDA Compliance Flags

Every medical device shipping entry into the U.S. runs through the FDA’s PREDICT screening system, which scores each shipment based on product type, manufacturer history, and documentation accuracy. Multi-leg ocean shipments create more handoff points than air shipments, and each handoff is an opportunity for a data mismatch that elevates a risk score. In an environment where import scrutiny has increased significantly, documentation integrity is a material variable in whether a Class II shipment clears in 48 hours or sits at port for two weeks.

When the Math Actually Works for Air Freight

For Class II medical devices, the rate card comparison is the wrong starting point. When carrying costs on transit time, safety stock requirements, compliance hold risk, and sterility exposure are factored in, the effective cost premium of air over ocean narrows. And for devices with tight sterility windows, high per-unit value, or hospital customers with on-time delivery penalties, air frequently produces the lower true landed cost.

Ocean freight’s longer and less predictable lead times require significantly more safety stock to maintain service levels. That stock ties up capital and introduces its own carrying cost drag. Product lifecycle management that accounts for total supply chain cost regularly reveals that the working capital required to support an ocean-dependent inventory strategy costs more than the per-shipment savings the mode was supposed to generate.

Air freight’s tighter transit times allow leaner inventory postures, faster demand response, and lower risk of shelf-life attrition on sterile devices sitting in safety stock buffers.

Remington Medical’s contract manufacturing services are built around domestic production. See how leveraging our manufacturing solutions helps remove international shipping exposure and get your product to market.

Our Medical Device Contract Manufacturing

When Ocean Freight Makes Sense

Ocean freight is the right answer under the right conditions. The key is being precise about what those conditions are rather than defaulting to it as the cost-effective option without verifying the economics hold.

For Class II medical device shipping, ocean makes genuine sense when:

Volume and value density support it. High-volume, lower-unit-value Class II devices have cost profiles where ocean savings are real and carrying cost exposure is proportionally smaller.
Lead times are stable and planning horizons are long. Programs with well-established demand patterns and minimal urgency are better suited to absorb ocean freight’s variability without excessive safety stock.
Sterility and shelf-life constraints are minimal. Non-sterile devices, or those with sterility assurance periods long enough that a 40-to-45-day logistics cycle is a small fraction of shelf life, face substantially lower packaging integrity risk during ocean transit.
Safety stock has been explicitly costed. Organizations that have modeled the working capital cost of the safety stock required to buffer ocean variability have done the analysis correctly. Choosing ocean without running those numbers is where problems can arise.

The Freight Mode Question Is Really a Supply Chain Design Question

An OEM sourcing offshore is making the mode decision inside a constraint. The device has to cross an ocean either way, and both options carry the compliance exposure and lead time variability that international medical device freight entails. A turnkey manufacturing relationship that keeps production, sterilization, and distribution coordination under one domestic roof removes an entire layer of bio medical supply chain risk from the program entirely.

With ocean freight rates structurally elevated above pre-pandemic levels, FDA screening scrutiny increasing, and carrying costs rising, the economics of international medical device shipping have shifted in ways that make domestic manufacturing more competitive than it’s been in years.

The medical device supply chain strategy that made sense five years ago deserves a fresh look with current numbers, and the freight lane is a good place to start.

Build a Freight Strategy That Starts With the Full Cost Picture

If your freight mode decisions for Class II devices are based on rate comparisons rather than true landed cost modeling, your supply chain is likely carrying more cost than you realize.

Remington Medical works with OEMs ready to rethink how their devices get to market, from manufacturing through delivery. Reach out to our team to talk through your program and what a more cost-transparent supply chain strategy could look like.

Air Freight vs. Ocean Freight for Class II Medical Device Shipping

Why the Standard Freight Comparison Doesn’t Work for Class II Devices

What Ocean Freight Actually Costs for a Class II Device

Transit Time and Inventory Carrying Costs

Sterility Window and Packaging Integrity Risk

Documentation Exposure and FDA Compliance Flags

When the Math Actually Works for Air Freight

When Ocean Freight Makes Sense

The Freight Mode Question Is Really a Supply Chain Design Question

Build a Freight Strategy That Starts With the Full Cost Picture

Share This Post

More Like This

What OEMs Need to Know About Medical-Grade Material Sourcing With Tariffs

What a Customs Hold Is Really Costing Your Medical Device Supply Chain

How Offshore Sterilization and Lab Testing Can Delay Medical Device Launches

Where Tariff Risk Lives in Your Medical Device Supply Chain

Dual-Sourcing Doesn’t Work When Both Sources Are Offshore: Rethink

Why Choosing a U.S.-Based Contract Manufacturer Matters in a High-Tariff Trade Environment

How Contract Manufacturing for Medical Devices Accelerates Innovation

Scaling Production: How to Transition From Prototype to Manufacturing Medical Devices

Medical Device Compliance After Brexit: CE vs. UKCA

Get In Touch

Navigation

Recent Blogs